Biotech Archives - Page 667 of 795

3 minute read

Daré Bioscience Announces IDE Approval For A Single Arm, Open-Label Pivotal Contraceptive Efficacy Study Of Ovaprene, An Investigational Hormone-Free Monthly Intravaginal Contraceptive

October 10, 8:10 AM

Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that the U.S. Food & Drug Administration (FDA) approved an Investigational Device Exemption (IDE) application

DARE

1 minute read

scPharmaceuticals Announces FDA Approval Of FUROSCIX

By Bill Haddad

October 10, 8:06 AM

BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of

SCPH

2 minute read

IRADIMED CORPORATION Withdraws 510(k) With Plans To Resubmit After Further Discussions With FDA

By Bill Haddad

October 10, 8:00 AM

IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) today announced that the Company voluntarily withdrew its 510(K) application on October 5, 2022, for its next-generation MR IV pump. Roger Susi,

IRMD

1 minute read

Swissmedic Approves Bivalent COVID-19 Booster Vaccine From Pfizer

By Bill Haddad

October 10, 7:42 AM

-Reuters

BNTX

1 minute read

Immatics Reports Interim Clinical Data Update On ACTengine IMA203 TCR-T Monotherapy Targeting PRAME

By Benzinga Newsdesk

October 10, 7:36 AM

Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses in different solid cancers, in patients with high and low PRAME expression Update covers data from

IMTX

1 minute read

Iovance Biotherapeutics Announces First Patient Dosed With PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy

By Bill Haddad

October 10, 7:30 AM

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that the first patient was dosed, and completed the safety observation

IOVA

2 minute read

Castle Biosciences To Present Data Supporting The Clinical Value Of Its Suite Of Skin Cancer Tests Through Multiple Oral Presentations At The 2022 American Society For Dermatologic Surgery Annual Meeting

By Benzinga Newsdesk

October 10, 7:06 AM

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, is presenting data highlighting its portfolio of skin cancer gene expression profile (GEP) tests at the

CSTL